AIM announces approval of patent for Ampligen in Japan

AIM ImmunoTech (AIM) announced that the Japan Patent Office has fully approved a Japanese patent covering the Company’s proprietary use of Ampligen in combination with checkpoint inhibitors for the treatment of cancer. The patent was granted in September 2025, but had to then pass a 6-month opposition period. Japan is one of the largest health markets in the world, with Japan and the United States expected to experience the greatest increase in global pancreatic cancer burden by 2030. The Japan patent expires December 20, 2039. The allowed claims in Japan cover an agent for treating cancer consisting of Ampligen in combination with a checkpoint inhibitor. The claims are broad and encompass multiple cancer types – including pancreatic cancer. AIM also holds a U.S. patent for methods involving the use of Ampligen as part of a combination oncology therapy when paired with an anti-PD-L1 antibody and a patent in the Netherlands for the use of Ampligen as a combination cancer therapy with checkpoint blockade inhibitors, such as Keytruda, Opdivo and Imfinzi. AIM also intends to expand its intellectual property portfolio by pursuing orphan drug designation in Japan for Ampligen in the treatment of pancreatic cancer.